BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamada Y, Abe R, Okano Y, Miyakawa Y. Long-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome. Intern Med 2017;56:1085-8. [PMID: 28458317 DOI: 10.2169/internalmedicine.56.7862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Wada H, Shiraki K, Matsumoto T, Shimpo H, Yamashita Y, Shimaoka M. The evaluation of a scoring system for diagnosing atypical hemolytic uremic syndrome. Thrombosis Update 2020;1:100012. [DOI: 10.1016/j.tru.2020.100012] [Reference Citation Analysis]
2 Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial 2019;23:4-21. [PMID: 30294946 DOI: 10.1111/1744-9987.12763] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
3 Kwong YD, Liu KD, Hsu RK, Johansen KL, McCulloch CE, Seth D, Fallahzadeh MK, Grimes BA, Ku E. Recovery of Kidney Function Among Patients With Glomerular Disease Starting Maintenance Dialysis. Am J Kidney Dis 2021;77:303-5. [PMID: 32771649 DOI: 10.1053/j.ajkd.2020.06.012] [Reference Citation Analysis]